he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:癫痫患者手术评估新型工具
下一页:癫痫失神发作有哪些腹泻呢
- 2022-04-28儿童癫痫的发病主因有哪些
- 2022-04-26纯红再障的诊断标准规范是什么
- 2022-04-25癫痫的初时的症状有哪些
- 2022-04-202013年亚太地区抗癫痫联合会抗癫痫药使用指南
- 2022-04-11综述:癫痫持续状态诊治最新进展
- 2021-11-05癫痫病的饮食原则需要同样什么
- 癫痫患者手术评估新型工具
- 合肥京东方医院泌尿科成功减少肥大增生患者「肥」
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 综述:癫痫持续状态诊治最新进展
- 抗癫痫药物预防新发癫痫:任重而道远
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- FDA批准Aptiom用于治疗患者癫痫发作
- 疾病新知:毛囊性白癜风
- 精彩幻灯:一网打尽妇科常见病
- 肺源性心脏病可能并发左心功能不全吗?如何制定治疗方案?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 泡温泉时不能忽视的事情
- 内衣穿不对容易得乳腺癌(2)
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 为什么光疗能有效治疗白癜风?
- UCB的Vimpat癫痫新适应症在美国获批
- 如何调理结石比较好?饮食调理效果好!
- 月经性癫痫患者妊娠期癫痫控制更好
- 癫痫猝死:凶手是谁?
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 为什么身上有小白点 可能得了这种病?
- 不注意这些问题,吃多少药都没用!
- 非淋菌性炎的症状是什么
- Medpage Today:不同类型的抗癫痫药物更有利
- JAMA:阳性结果的文章一定更受关注吗?
- 癫痫吃什么食物好?
- 茎叶的好处 茎叶这些本领你都知道吗
- 羊角风的病人一定会怎么治疗才管用
- 癫痫病应该怎样治疗法 癫痫病治疗法要多少钱
- 癫痫病的症状有哪些 有这症状一般来说
- 癫痫疾病要怎么外科手术 癫痫病的药物选择
- 20130821山东卫视明目:许新升讲癫痫的危害
- 颞叶癫痫病如何用药 用药癫痫的药物有哪些
- 癫痫病有什么办法治疗 针对病症做治疗
- 国医养生堂:杨全兴讲如何防治儿童癫痫
- 羊癫疯能治好吗 治疗不易需要多加注意能避免发作
- 20130301山东卫视秘诀节目:安晓光谈癫痫病病因
- 癫痫病的常规治疗分析方法有哪些
- 癫痫病的早期症状 有这些症状轻轻癫痫病